Financials PREDILIFE

Equities

ALPRE

FR0010169920

Biotechnology & Medical Research

Market Closed - Euronext Paris 07:03:19 02/05/2024 pm IST 5-day change 1st Jan Change
15.9 EUR +208.74% Intraday chart for PREDILIFE +285.92% +178.95%

Valuation

Fiscal Period: December 2021 2022
Capitalization 1 25.17 58.84
Enterprise Value (EV) 1 25.17 22.91
P/E ratio -7.42 x -
Yield - -
Capitalization / Revenue - 67.2 x
EV / Revenue - 79.4 x
EV / EBITDA - -6.57 x
EV / FCF - -7.41 x
FCF Yield - -13.5%
Price to Book - -
Nbr of stocks (in thousands) 3,648 3,701
Reference price 2 6.900 15.90
Announcement Date 29/04/22 28/04/23
1EUR in Million2EUR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2021 2022
Net sales 1 - 0.2886
EBITDA 1 - -3.485
EBIT 1 - -3.504
Operating Margin - -1,214.17%
Earnings before Tax (EBT) - -
Net income -3.414 -
Net margin - -
EPS -0.9300 -
Free Cash Flow 1 - -3.092
FCF margin - -1,071.39%
FCF Conversion (EBITDA) - -
FCF Conversion (Net income) - -
Dividend per Share - -
Announcement Date 29/04/22 28/04/23
1EUR in Million
Estimates

Balance Sheet Analysis

Fiscal Period: December 2021 2022
Net Debt 1 - 3.52
Net Cash position 1 - 6
Leverage (Debt/EBITDA) - -1.01 x
Free Cash Flow 1 - -3.09
ROE (net income / shareholders' equity) - -
ROA (Net income/ Total Assets) - -
Assets - -
Book Value Per Share - -
Cash Flow per Share - -
Capex 1 - 0.03
Capex / Sales - 9.35%
Announcement Date 29/04/22 28/04/23
1EUR in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Annual profits - Rate of surprise